Quick Answer
ANAPTYSBIO, INC reported Total Revenue of $234.60 million for fiscal year 2025.
ANAPTYSBIO, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $234.60M +157.0% |
$91.28M +432.0% |
$17.16M +66.8% |
$10.29M -83.7% |
$63.17M -15.8% |
$75.00M +837.5% |
| Revenue (ASC 606) | $234.60M +157.0% |
$91.28M +432.0% |
$17.16M +66.8% |
$10.29M -83.7% |
$63.17M -15.8% |
$75.00M +837.5% |
| Net Income | -$13.23M +90.9% |
-$145.23M +11.2% |
-$163.62M -27.1% |
-$128.72M -122.7% |
-$57.80M -190.0% |
-$19.93M +79.5% |
| Diluted EPS | -$0.46 +91.0% |
-$5.12 +15.8% |
-$6.08 -33.0% |
-$4.57 -116.6% |
-$2.11 -189.0% |
-$0.73 +79.7% |
| Total Assets | $364.39M -24.7% |
$483.83M +7.0% |
$452.39M -25.9% |
$610.38M -5.1% |
$643.07M +54.4% |
$416.55M -4.3% |
| Cash and Equivalents | $238.20M +93.5% |
$123.08M +242.2% |
$35.97M -49.6% |
$71.31M -85.6% |
$495.73M +97.9% |
$250.46M +46.5% |
| Stockholders Equity | $37.21M -47.5% |
$70.87M -19.6% |
$88.10M -66.4% |
$262.10M -26.5% |
$356.43M -10.2% |
$396.73M -2.0% |
| R&D Expense | — | — | — | $88.80M -9.8% |
$98.50M +23.1% |
$80.03M -19.4% |
| Operating Income | $47.90M +141.7% |
-$114.95M +30.1% |
-$164.41M -42.8% |
-$115.15M -102.7% |
-$56.81M -137.9% |
-$23.88M +77.8% |
| Shares Outstanding | 28.02M -8.1% |
30.47M +14.6% |
26.60M -6.7% |
28.51M +3.1% |
27.65M +1.1% |
27.36M +0.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $76.32M | +154.3% | +242.8% |
| Revenue (ASC 606) | September 30, 2025 | $76.32M | +154.3% | +242.8% |
| Net Income | September 30, 2025 | $15.11M | +146.0% | +139.1% |
| Diluted EPS | September 30, 2025 | $0.52 | +145.6% | +138.8% |
| Total Assets | September 30, 2025 | $353.10M | -28.4% | +5.3% |
| Cash and Equivalents | September 30, 2025 | $109.83M | -42.7% | +147.9% |
| Stockholders Equity | September 30, 2025 | -$29.42M | -134.9% | +34.2% |
| R&D Expense | September 30, 2025 | $31.41M | -25.6% | -17.0% |
| Operating Income | September 30, 2025 | $34.70M | +252.5% | +232.6% |
| Shares Outstanding | September 30, 2025 | 27.58M | -9.4% | -1.4% |
- ANAPTYSBIO, INC reported Total Revenue of $234.60 million for fiscal year 2025.
- ANAPTYSBIO, INC showed an increase of +157.0% in Total Revenue compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Revenue (ASC 606) of $234.60 million for fiscal year 2025.
- ANAPTYSBIO, INC showed an increase of +157.0% in Revenue (ASC 606) compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Net Income of -$13.23 million for fiscal year 2025.
- ANAPTYSBIO, INC showed an increase of +90.9% in Net Income compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Diluted EPS of $0.46 per share (loss) for fiscal year 2025.
- ANAPTYSBIO, INC showed an increase of +91.0% in Diluted EPS compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Total Assets of $364.39 million for fiscal year 2025.
- ANAPTYSBIO, INC showed a decrease of -24.7% in Total Assets compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Cash and Equivalents of $238.20 million for fiscal year 2025.
- ANAPTYSBIO, INC showed an increase of +93.5% in Cash and Equivalents compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Stockholders Equity of $37.21 million for fiscal year 2025.
- ANAPTYSBIO, INC showed a decrease of -47.5% in Stockholders Equity compared to the prior fiscal year.
- ANAPTYSBIO, INC reported R&D Expense of $88.80 million for fiscal year 2022.
- ANAPTYSBIO, INC showed a decrease of -9.8% in R&D Expense compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Operating Income of $47.90 million for fiscal year 2025.
- ANAPTYSBIO, INC showed an increase of +141.7% in Operating Income compared to the prior fiscal year.
- ANAPTYSBIO, INC reported Shares Outstanding of 28.02 million shares for fiscal year 2025.
- ANAPTYSBIO, INC showed a decrease of -8.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: